SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as former President Trump's immediate re-imposition of global tariffs, following a Supreme Court setback, sparks significant market uncertainty and international trade tensions, with community sentiment divided between loyal support and strong opinions labeling the stock as a volatile "scam" amidst broader political and economic concerns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is surging following overwhelmingly positive Phase 2 trial results for sonelokimab in axial spondyloarthritis, which showed high efficacy and potential for disease modification, leading the community to anticipate significant re-valuation and a potential short squeeze ahead of an upcoming Investor Day.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following rapid EU and Saudi Arabian approvals for its Anktiva therapy, which has ignited community discussion around massive global revenue potential, a looming short squeeze, and the company's aggressive expansion into new cancer indications and robotic manufacturing.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is trending higher on the heels of strong financial results and significant new defense contract awards, with community discussion centered on the aerospace and defense leader's pivotal role amidst escalating global tensions and renewed proposals for substantially increased military budgets.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as its AI chip unit, Kunlunxin, has confidentially filed for a Hong Kong IPO, a move expected to unlock significant value and capitalize on China's AI push. The community is also buzzing about the company's new substantial share repurchase program and its inaugural dividend policy, which are seen as strong commitments to shareholder returns.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed following its decision to pause the planned company split and a mixed earnings report with soft 2026 guidance, creating a split in community sentiment between those who view its high dividend and defensive attributes as a "safety play" and others concerned by increasing private-label competition and the overhang of a potential Berkshire Hathaway stake sale.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

The recent Q4 earnings report and the CEO's strategic vision for an AI-powered, capital-light real estate platform, including a new mortgage product in beta, are driving intense conversation around Opendoor, with bulls embracing the company's operational transformation and institutional backing, while bears highlight continued unprofitability and the historical challenges of the iBuying model.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending amidst a tug-of-war between optimists seeing further upside and those anticipating a sharp pullback, fueled by evolving tariff uncertainties and mixed economic data. Community discussion highlights concerns over extreme market optimism and institutional hedging despite recent strength, signaling a pivotal moment for small-cap performance.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after its Bysanti drug secured FDA approval for bipolar I disorder and schizophrenia, backed by New Chemical Entity status and patent protection through 2044. The community is actively discussing its potential for a significant valuation re-rating, a short squeeze given high short interest, and the increasing likelihood of a buyout by larger pharmaceutical companies seeking long-term revenue streams.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to reports of record-breaking battery swap numbers during the Chinese New Year holiday, fueling bullish sentiment around its BaaS model and potential for profitability, further supported by D.E. Shaw significantly increasing its institutional stake. The community actively debates the long-term sustainability of these swap figures and the stock's persistent battle around the $5 mark, amidst ongoing discussions of market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Arrow Aviation provides private flights to the public sector, with specialized operations such as air ambulances.</li><li>The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation.</li><li>The MoU also grants options to acquire the remaining 49% after two years, Polyrizon said.</li></ul>Shares of Polyrizon (PLRZ) gained 6% in premarket trading on Tuesday after the company announced that it recently signed a memorandum of understanding to acquire a 51% stake in global private aviation firm Arrow Aviation through a cash investment of NIS 18 million ($5.8 million).“We believe that this strategic move, upon completion, represents an exciting diversification opportunity for Polyrizon, allowing us to leverage our strong financial position to enter the dynamic private aviation market, a market set to grow to $41.38 billion by 2030, through a potential acquisition of a high-growth, high-potential company,” said Tomer Izraeli, CEO of Polyrizon.<h2 class="st-heading-2">Deal Rationale</h2>Arrow Aviation provides private flights to the public sector, with specialized operations including air ambulances, medical evacuations, rescue missions, special-needs transport, medical tourism, and cargo services, including the transport of sensitive and hazardous materials under special licenses.The company last reported annual unaudited revenues of around $19 million and adjusted earnings before interest, tax, depreciation and amortization (EBITDA) of around $3 million.The deal includes transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation in exchange for a convertible note issued by Polyrizon.&nbsp;Arrow Aviation shareholders will also forgive outstanding debts for convertible notes, allowing the company to operate debt-free after closing. The MoU grants options to acquire the remaining 49% after two years, with a definitive agreement expected within 30 days, subject to due diligence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits turned 'neutral' from 'bullish' a day earlier.One user noted the increasing volumes traded and the company's market cap.<stembedurl>https://stocktwits.com/raulaa/message/644568154</stembedurl><a href="https://stocktwits.com/symbol/PLRZ">PLRZ shares</a> have gained more than 66% so far this year.$1 = NIS 3.1For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business?

The company announced that it recently signed an MoU to acquire a 51% stake in private aviation firm Arrow Aviation for around $5.8 million.

Equity

<ul class="summary-bullets"><li>Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74.</li><li>Sales of the Eylea declined amid competitive pressure and a shift of patients to the high-dose version.</li><li>Sanofi collaboration revenue rose 35% as the company received a larger share of profits from jointly commercialized antibody drugs.</li></ul>Regeneron Pharmaceuticals (REGN) reported a better-than-expected fourth-quarter (Q4) print, as higher sales from its collaboration with&nbsp;Sanofi and Eylea HD injections offset lower revenue from Eylea, which is&nbsp;marketed outside the U.S. by Bayer.Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74.<a href="https://stocktwits.com/symbol/REGN">REGN shares</a>&nbsp;were 2.6% lower in pre-market trading on Friday, while retail sentiment on Stocktwits remained ‘neutral’ over the past 24 hours.<h2 class="st-heading-2">Revenue Breakdown</h2>Eylea HD sales climbed 66% in the fourth quarter as strong demand lifted volumes, though gains were partly offset by lower pricing. In contrast, sales of the Eylea declined 52% amid competitive pressure, a shift of patients to the high-dose version, and affordability-driven use of cheaper alternatives, the company said.Eylea is a prescription medicine injected into the eye to treat conditions like Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME). Eylea HD is a higher-dose and longer-lasting version of Eylea.Sanofi collaboration revenue rose 35% as the company received a larger share of profits from jointly commercialized antibody drugs, driven primarily by stronger sales of Dupixent, used to treat eczema.“In the fourth quarter, we secured label expansions and new filler solutions for EYLEA HD, further enhancing its commercial potential. Dupixent received new approvals in Japan and Europe and is currently the most widely used innovative branded antibody medicine, with over 1.4 million active patients worldwide,” said Leonard S. Schleifer, President and CEO of Regeneron.The company also forecast non-GAAP R&amp;D costs of $5.90-$6.10 billion for full-year 2026, significantly higher than $5.15 billion in FY2025. The company has around 45 product candidates in clinical development, it added.<h2 class="st-heading-2">Stock Watch</h2>On Thursday, TD Cowen raised its price target on Regeneron to $820 from $800 and maintained a ‘Buy’ rating. This implies a&nbsp;12%&nbsp;upside&nbsp;from the current trading price.The stock has gained 9.2% over the past year, but is down 3.2% year to date.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/silver-sees-sharp-decline-as-dollar-gains/cmyS0BER4Sb"> Silver Plummets 18% After Weeks Of Relentless Rally – AG, HL, PAAS Stocks Also Dragged Lower&nbsp;</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock 

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

A High-Dose Bet Is Paying Off For Regeneron, But Core Eylea Weakness Caps Upside

Should You Invest in the VanEck Biotech ETF (BBH)?

VanEck Announces Year-End Distributions for VanEck Equity ETFs

VanEck announced today the following 2025 annual distributions per share for its VanEck equity exchange-traded funds. Distributions Per Share for the VanEck ETFs Listed Below Ex-Date: December 22...

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

BBH
VanEck Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BBH News

BBHVanEck Biotech ETF